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(From The Laboratory  of Clinical Investigation,  National Institute of Allergy and Infectious 
Diseases, National Institutes of Health, Bethesda,  Maryland 20014) 
Understanding the events involved in the activation of human bone marrow- 
derived (B) lymphocytes  to antibody formation and secretion has been hampered 
by the lack of a simple reprDducible method of culture and assay. In the mouse 
model,  induction  of primary in  vitro  antigenic  stimulation  (1), as  well  as 
polyclonal B-cell  activation  (2,  3),  with measurement of single cell  antibody 
production by plaque-forming cell (PFC) ~  assays has allowed for in depth prob- 
ing of the mechanisms of B-cell activation.  Such a  simple and reproducible 
methodology has not been available for human studies.  A  few reports have 
appeared describing primary in vitro activation of human B lymphocytes from 
various  organs,  particularly tonsil,  by  soluble  or particulate  antigens  with 
subsequent measurement of antibody response by a PFC assay (4-8). However, 
these studies have been quite difficult to reproduce, and subsequent follow-up 
studies  have  not  appeared.  In  addition,  recent studies  have  pointed  out  a 
potential area of significant artifact in primary in vitro stimulation of human 
cultures with sheep red blood cells (SRBC) (9). Attempts to establish PFC assays 
after polyclonal activation of human B  lymphocytes have met with similar 
difficulties  (10). No  reproducible studies  have  appeared  which demonstrate 
single cell antibody production by human lymphocytes after activation with 
polyclonal B-cell activators as measured by a PFC assay. 
The present report describes the conditions necessary for the in vitro induc- 
tion of polyclonal activation as well as antigenic stimulation of human tonsillar 
lymphocytes with measurement of antibody production by a direct PFC assay. 
The methods are simple and the results reproducible. Critical factors for induc- 
tion and assay are delineated and areas of potential artifact are described. This 
system can be readily employed to explore the complex events associated with 
human B-lymphocyte activation. 
Materials and Methods 
Tonsils.  Tonsils were obtained from  subjects undergoing routine tonsillectomy for chronic 
tonsillitis. Tissue was placed  immediately in ice-cold RPMI-1640 (Grand Island Biological  Co., 
1  Abbreviations  used in this paper: FCS, fetal calf serum; FITC, fluoresceinated isothiocyanate; 
HBSS, Hanks' balanced salt solution; KLH, keyhole limpet hemocyanin;  LPS, lipopolysaccharide; 
NIP, 4-hydroxy-3-iodo-5-nitrophenylacetic  acid; PFC, plaque-forming cell; PPD, purified protein 
derivative of tuberculin; PWM,  pokeweed  mitogen; SIII, pneumococcal  polysaccharide;  TNP, 
trinitrophenyl. 
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Grand Island,  N. Y.)  supplemented with 100 U/ml penicillin  and 100 ~g/ml streptomycin sulfate. 
Processing  of  cell  suspensions was  always  begun  within  30  rain  of  surgical  removal  of  the  tonsils. 
Cell  Suspensions.  Tonsils  were  teased  apart  with  forceps  in  a Petri  dish  in  cold  RPMI-1640  and 
clumps dispersed  by repeated aspirations  through a pipette.  Debris  was removed by passing the 
cell suspension through sterile  gauze followed by further purification  using standard Ficoll- 
Hypaque density centrifugation  (11).  Differential  counts of the cell  suspensions were done on 
cytocentrifuge  preparations stained with Wright's stain. 
Culture Conditions.  Cultures for  the determination of  antibody synthesis  were  performed  in  a 
modified Mishell-Dutton system (1).  The precise  requirements for optimal culture  conditions  in 
this  system, as  well  as  the  effect  of  variation  of  factors  such  as  media, sera,  cell  density,  and time 
in  culture  will  be  described  below. Basically,  cultures  were  performed  as  follows:  cultures  were  set 
up in multi-well (1.5-cm  diameter wells),  fiat  bottom plastic  plates  (Linbro Scientific  Inc.,  New 
Haven, Conn.). 5 × 10  B  cells  in 2 ml of  RPMI-1640 containing 1% trypticase  soy broth,  0.02  M  L- 
glutamine, 100 U/ml penicillin,  and 100 ~g/ml streptomycin sulfate  were placed into  each well. 
Cell  densities  ranging  from  0.1  to 10 × 106  were  tested  and 5 × 106  proved  optimal.  Cultures were 
evaluated with serum-free media as well as with serum supplements at various concentrations. 
Two main categories  of sera were tested:  fetal  calf  serum (FCS) obtained from International 
Biological  Laboratories Inc.,  Rockville,  Md. and from Colorado Serum Co., Denver, Colo.;  and 
various lots  of  pooled lluman AB serum obtained from International  Biological  Laboratories Inc. 
and University Plasma Center, College Park, Md., as  well  as  sera  from  individual  AB donors.  All 
sera were heat inactivated  at 56°C for  45 rain,  passed through Millipore  filters,  and either  used 
directly  or  after  repeated absorptions with SRBC. 
In  every  experiment, cultures  were stimulated with  either  pokeweed  mitogen (PWM) lot  153601 
or  254004 (GIBCO) in  a wide  concentration  range, or  SRBC in  various  concentrations  ranging  from 
0.1 to 10 x 10  ~  per culture.  In some experiments cultures  were stimulated with one of  several 
substances known to  be  B-cell  activators  in  mouse  culture  systems (3).  These  included  Escherichia 
coli 0 128:B12 lipopolysaccharide  (LPS), lot  617124 (Difco  Laboratories,  Detroit,  Mich.);  purified 
protein derivative of tuberculin (PPD), lot A10 (Connaught Research Laboratories, Toronto, 
Canada); keyhole  limpet hemocyanin (KLH), lot  SPH 95 (Pacific  Bio-Marine Supply Co.,  Venice, 
Calif.);  dextran  sulfate  (DxSO4)  (Pharmacia  Fine  Chemicals  Ltd.,  Uppsala,  Sweden);  and  pneumo- 
coccal  polysaccharide (SIII)  (gift  of  Dr. Phillip  J. Baker, National  Institutes  of  Health, Bethesda, 
Md.). 
Cultures were  incubated for  durations  of  1-10  days  on  a rocker  platform (7  cycles/rain)  at  37°C  in 
5% CO2 in air  at 100% humidity. At the end of  the culture  period,  cells  were harvested from the 
plates  by gentle scraping with a rubber policeman followed by repeated aspirations  through a 
Pasteur pipette.  Cells  were transferred  to plastic  tubes, washed twice in cold  RPMI-1640, and 
brought to  the appropriate concentration  for  the plaque assay.  Cultures for  the determination of 
blast  transformation as measured by tritiated  thymidine incorporation  were set  up in microtiter 
plates  and performed as previously  described (12). 
Assay for PFC.  Cell  suspensions from cultures  stimulated either  with polyclonal B-cell 
activators  such  as  PWM  or  particulate  antigen  such  as  SRBC were assayed  for  direct  PFC against 
SRBC by  a modification  of  the  Jerne-Nordin  hemolysis-in-gel  method (13)  employing  an  ultra-thin 
layer gel technique. After heating to boiling,  0.7 ml of  0.5% Noble agar (Difco  Laboratories)  in 
Hanks' balanced salt solution (HBSS) (NIH media supply section)  containing 0.05% DEAE- 
dextran (Pharmacia Fine Chemicals Ltd.)  was added to Falcon tubes (no.  2052;  Falcon Plastics, 
Div. of BioQuest, Oxnard, Calif.)  and kept at 46°C.  Thereupon, 0.05  ml of  indicator  red cells 
diluted  1:5  in HBSS (20% suspension),  0.2  ml of  the cell  suspension in  the appropriate  concentra- 
tion,  and 0.05  ml of  guinea pig serum (previously  absorbed with SRBC) diluted 1:4 in veronal- 
buffered saline  were added to each tube (14).  The mixture was then plated as follows:  three 
separate 0.2 ml drops were placed on plastic  Petri  dishes (no. 1001;  Falcon Plastics,  Div. of 
BioQuest).  A 22 × 32  mm  glass  cover  slip  (Exax  No. i  cover  glass;  Kimble Glass Company, Toledo, 
Ohio) was  immediately  placed  on  each  drop.  By  capillary  action,  the  drop  spread into  an  ultra-thin 
layer  beneath the cover slip.  Plates were incubated for  3 h at 37°C and PFC were counted on a 
dissecting  microscope using indirect  light. 
In some experiments  the SRBC were haptenated with one of  several  haptens in an attempt  to 
increase  the  sensitivity  of  the  assay for  polyclonal  B-cell  activation  after  PWM  stimulation.  The  4- 
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(FITC) hapten were conjugated to SRBC as previously described (15),  and trinitrophenyl (TNP) 
haptenation was carried out as previously reported (16). 
Inhibition  of PFC.  The  functional and  metabolic requirements for antibody synthesis and 
secretion were determined by subjecting the cultures to a variety of inhibitory manipulations (17). 
In some experiments cells were heat killed at 56°C for 30 min before assay. In others, complement 
(C) was not added, or the plaquing assay was conducted at room temperature or at 4°C instead of at 
37°C.  In a group of other experiments, 24 h before harvesting, cell cultures were either irradiated 
with 5,000 R or one of the following inhibitors were added: mitomycin C, 4 and 40 t~g/ml (Sigma 
Chemical Co., St. Louis, Mo.); puromycin, 1 and 10 tLg/ml (Sigma Chemical Co.); actinomycin D, 
0.5 and 5 tLg/ml (Sigma Chemical Co.); and cycloheximide, 1 and 10 tLg/ml (Sigma Chemical Co.). 
Addition  of Allogeneic  Cells.  In  some  experiments,  1  x  106  mitomycin  C-treated,  Ficoll- 
Hypaque-separated peripheral blood mononuclear cells from an unrelated donor were added to the 
cultures at day 0. This was done in order to determine the effect of a simultaneous mixed leukocyte 
reaction (in vitro allogeneic effect) on ongoing antibody synthesis. 
Results 
Cell Suspensions.  After Ficoll-Hypaque gradient centrifugation of the cell 
suspensions from both tonsils of a  single individual, the mean _+  SEM yield of 
mononuclear  cells  from  35  subjects  was  1.5  _+  0.3  x  109. Cell  viability  as 
measured by trypan blue dye exclusion was always greater than 90%. The cell 
suspensions contained 91  _+ 0.7% lymphocytes, 5 -  0.6% lymphoblast-like cells, 
3.8  +_ 0.4% monocytes, and from 0 to 2% plasma cells. 
Culture Conditions.  A cell density of 5 x  106 cells per well was optimal and 
peak PFC responses were usually found with PWM concentrations between 1:20 
and 1:1,000 final dilutions. In cultures stimulated with SRBC, concentrations of 
1-5  x  l0  s SRBC per well were optimal. Addition of HEPES buffer or feeding of 
cultures with nutrient cocktail was not necessary. In none of the experiments 
was a substantial PFC response detectable during the first 2 days of culture. By 
3  days small  responses were detected which peaked sharply at  5-7  days and 
began declining by 8 days. 
The nature of the serum supplementation was clearly of utmost importance. 
All  lots  of pooled  human  AB  sera  were  freshly  drawn  as  were  sera  from 
individual AB donors. Cells did not survive and no PFC were detected if serum 
was not added to cultures. The addition of 2-mercaptoethanol did not substitute 
for serum.  Background  PFC  were  higher  with  FCS  than  with  most  lots  of 
human AB serum and concentrations of 10% human AB serum proved optimal. 
An observation made during the course of these studies was that absorption of 
serum with SRBC before culture removed a  suppressant factor from the serum 
and  increased  (up  to  20-fold)  the  ability of that  serum  to  support the  PFC 
response of cultures activated with various stimuli. This enhancement of PFC 
response was seen without significantly increasing background PFC. This phe- 
nomenon will be described below. 
Assay for PFC.  The combined gel-cover slip method proved to be sensitive, 
reproducible, and quite simple to perform and read. The clarity of the plaques, 
as well as the demonstration of a  single mononuclear cell in the center of a 
plaque is shown in Fig.  1. It is important to emphasize that in the first several 
experiments a  mononuclear cell was  identified in the  center of every plaque 
before calling it a true plaque. Subsequently, in all experiments representative 
plaques on every plate were checked for a cell in the center. Such an approach 
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FIG.  1.  (a) Appearance of  plaques in ultra-thin agar gel layer beneath a glass cover slip. x 
6.5.  (b) Single mononuclear cell in the center of a typical plaque from a  PWM-stimulated 
culture of human tonsillar lymphocytes, x  200. 
there were considerable difficulties in obtaining plaques in cultures of human 
lymphocytes. In addition,  under certain conditions in which SRBC were used as 
the  stimulus,  artifactual  plaques  could be demonstrated  as will be discussed 
below.  Plaques  were detectable by 30  min  and  reached  maximal  clarity  and 
number by 2-3 h. 
Demonstration of Artifactual Plaques.  As has recently been pointed out by 
Muchmore  et  al.  (9),  human  lymphocyte  cultures  stimulated  with  SRBC  in 
which the serum or plasma supplement has not been absorbed with the immu- 
nizing SRBC can result in artifactual plaques. We have found this to be the case 
in our culture system. The mechanism of formation of artifactual plaques is an 
agglutination of stimulator SRBC in culture by anti-SRBC antibody present in 
the  serum  supplement.  When  the  lymphocytes are  prepared  for  the  plaque 
assay,  these  aggregates  are  carried  over  and  after  setting  in  the  gel,  the 
antibody diffuses out  symmetrically,  attaching  to the  indicator  SRBC.  Upon 
addition of C, a plaque is formed which usually does not have a mononuclear cell 
in  the  center.  Thus,  absorption  of sera  with  SRBC  was  essential  from  two 
standpoints, the removal of blocking factors mentioned above, and the elimina- 
tion of artifactual plaques  (Table I). 
Inhibition ofPFC.  Formation of true plaques was inhibited by greater than 
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TABLE  I 
Effect of  Absorption of  Human AB Serum with SRBC on the PFC Response to PWM and 
SRBC Stimulation 
Stimulus 
True plaques  Artifactual plaques 
Unabsorbed*  Absorbed  Unabsorbed Absorbed 
serum  serum  serum  serum 
None (background)  15  9  0  0 
PWM  15  210  5  0 
SRBC  9  148  2,850  0 
* 10% human AB serum used in all cultures. 
$ PFC/10  ~  lymphocytes. 
resulted in complete abrogation of plaques. Plaques in assay plates incubated at 
room temperature rather than 37°C were decreased by approximately 50% and 
were smaller and  less clear.  Incubation at 4°C  resulted in greater than  95% 
suppression of PFC.  Irradiation of cultures with 5,000  R  the day before assay 
resulted  in  greater than  75%  suppression  of PFC  numbers.  The  addition  of 
inhibitors which affect protein synthesis such as puromycin, cycloheximide, and 
actinomycin D 24 h  before assay in concentrations which did not significantly 
reduce  viability  resulted  in  from  50  to  90%  suppression  of PFC  numbers. 
Mitomycin C at a concentration of 4-40 ~g/ml, when added at day 0 resulted in 
death of the cultures by day 5.  When added 18 h  before harvesting, it did not 
affect the number of PFC. 
PFC Response to PWM Stimulation.  The anti-SRBC response elicited by the 
polyclonal activation  of tonsillar  lymphocytes by  PWM  as  compared  to  the 
response to specific stimulation by SRBC is shown in Fig. 2. It is of interest that 
when  the  conditions  described  above  for  avoiding  artifactual  plaques  after 
stimulation with SRBC  were met,  the magnitude of the anti-SRBC  response 
after polyclonal activation by PWM  was  as  great  or greater than  that  after 
antigenic stimulation with SRBC. 
In several experiments, an attempt was made to increase the sensitivity of  the 
PFC assay after PWM stimulation by coupling various haptens such as TNP, 
NIP, and FITC to the target SRBC. There was no difference in numbers of PFC 
when TNP-SRBC was used as the indicator as opposed to unconjugated SRBC. 
The coupling of NIP or FITC haptens to SRBC resulted in approximately a 30- 
40% increase in numbers of detectable PFC in a  few assays, but this was not 
consistent. 
Allogeneic Effect.  The effect of adding 1  ×  106 mitomycin C-treated Ficoll- 
Hypaque-separated peripheral blood mononuclear cells from an unrelated donor 
to the 5  ×  106 tonsillar lymphocytes per well on the PFC response to SRBC or 
PWM  stimulation  is  shown  in  Fig.  3.  The  number of background  PFC  was 
unchanged (P >  0.2, Student's t test). There was a  variable and nonsignificant 
(P  >  0.2)  effect on the PWM-stimulated cultures,  although there was clearly 
suppression  seen  in  some  experiments.  In  contrast,  there  was  a  significant 
enhancing effect (P  <  0.05) on the SRBC-stimulated cultures. 
Blast  Transformation  and  PFC Response.  In  PWM-stimulated  cultures, 
peak blast transformation consistently preceded peak PFC response by 1 to 2 679 
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TABLE  II 
PFC Response of Human Tonsillar Lymphocytes  to Various B- 
Cell Activators 
Stimulus  PFC/106 lymphocytes 
Background  13  -+ 5* 
LPS  82  _+  21 
PPD  91  -+ 33 
KLH  21  -+  5 
SIII  9  _+  3 
DxSO4  3  -+  2 
* Mean  _*  SEM of 10 tonsils. 
days. Stimulation with SRBC rarely resulted in a detectable blast transforma- 
tion response of greater than three to four times above background. 
PFC Response to Other Polyclonal B-Cell Activators.  The PFC responses of 
human tonsillar lymphocytes to various substances known to be B-cell activa- 
tors  in  mice  are  shown  in  Table  II.  Stimulation with  LPS  and  PPD  gave 
significant increases over background (P  <  0.01 and P  <  0.05,  respectively). 
Optimal stimulatory concentrations varied among different tonsils. In general, 
peak PFC responses were seen at concentrations of LPS from 50 to 500  tLg/ml 
and  PPD  from  10  to  50  t~g/ml.  When  mean  responses  of 10  subjects  were 
compared, KLH stimulation did not result in a  significant PFC response (P  > 
0.2).  However,  certain individuals manifested a  substantial increase  in PFC 
response over background after stimulation with KLH. SIII and DxSO4 did not 
activate cultures to PFC responses. Of interest was the fact that none of these 
substances stimulated cultures significantly to blast transformation at 3 or 5 
days as measured by tritiated thymidine incorporation except for KLH, which 
occasionally resulted in a  blast transformation response of up to fivefold over 
background. 
All these substances were tested for the presence of endotoxin by the limulus 
assay as previously described (18) (assays kindly done by Dr.  Ronald J. Elin, 
NIH, Bethesda, Md.). LPS contained endotoxin as expected. SIII (50 t~g/ml) and 
PPD  (500 t~g/ml)  had nanogram quantities, while the highest used concentra- 
tions of KLH and DxSO4 had no detectable endotoxin. Of note also is the fact 
that PWM in the concentrations used in the present studies did not contain de- 
tectable endotoxin. 
Discussion 
The present study clearly demonstrates that human B  lymphocytes can be 
successfully and reproducibly activated in vitro and subsequently assayed for 
antibody production by a direct PFC assay against SRBC targets. This can be 
accomplished by specific stimulation with an antigen such as SRBC, and even 
more so by polyclonal activation of lymphocytes with PWM.  Also,  successful 
induction and PFC assay of antibody production follows stimulation with other 
substances which have been shown to be B-cell activators in the mouse (3) and 
which  have  not  been  consistently shown  to  activate  B  cells  in  humans  as 
measured by the standard thymidine incorporation assays for blast transforma- 
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assay would be of great  interest  and  importance  in  the  investigation  of the 
mechanisms  of B-cell  activation  in  humans,  surprisingly  few  studies  using 
antigenic  stimulation  have  appeared.  Furthermore,  the  use of mitogens as a 
probe  in  the  study of B-cell activation  in  the  mouse  has  contributed  to our 
understanding in this area (3). The present study makes available such a model 
of mitogen-induced B-cell activation in humans adaptable to the PFC assay. 
The success of this model resulted from a combination of a methodical modifi- 
cation of the original Mishell-Dutton system (1) and almost chance discovery of 
certain critical factors. With regard to the culture conditions, it became evident 
that there was an optimal cell density, media composition, duration of culture, 
and concentration of stimulants.  However, the most critical factor was clearly 
the  sera employed.  Some batches  of serum  were strongly  supportive  of PFC 
responses to SRBC stimulation  as well as to polyclonal B-cell activation,  and 
other batches resulted in very poor responses.  In addition,  it was found that 
absorption of sera with SRBC resulted in most cases in a marked (up to 20-fold) 
increase in the ability of that sera to support PFC responses to SRBC. Clearly, 
most human sera contain a factor which markedly suppresses the PFC response 
to SRBC targets. This factor does not influence cell yield or viability of cultures 
and can be removed by absorption with SRBC. Although it is probable that this 
factor is antibody which reacts with SRBC determinants,  its precise nature is 
not entirely clear at present and is the subject of current investigation  (B.  F. 
Haynes and A.  S. Fauci, unpublished observations). Suffice it to say that this 
serum  inhibitory  factor probably was one of the critical  reasons  for previous 
difficulties  in  establishing  a  reproducible  PFC  assay  for  in  vitro  antibody 
synthesis against SRBC in human cultures. The importance of multiple absorp- 
tions  of supplemental  sera  with  SRBC becomes even  more critical  in SRBC- 
stimulated cultures in which the use of unabsorbed serum results in a decrease 
in true plaques and the appearance of large numbers of artifactual plaques as 
described in the present study and previously by Muchmore et al.  (9). 
The particular hemolysis-in-gel assay used in this study lends simplicity and 
clarity to the system. It combines the sensitivity of a monolayer technique with 
the stability and clarity of gel and appears to be well suited to the human PFC 
assay. 
The use of SRBC as stimulator and target in the PFC assay is the standard 
approach for primary in vitro sensitization of lymphocyte cultures (1,  17). The 
use of SRBC as targets for the measurement of antibody synthesis after poly- 
clonal B-cell activation  is .also well established in the mouse system  (3).  It is 
based on the premise that polyclonal B-cell activators stimulate lymphocytes to 
secrete antibodies with wide ranges  of specificities including  those that  react 
with determinants  on the SRBC. It is clear from the present study that this is 
also applicable to the  stimulation  of human  B  cells by polyclonal activators, 
particularly PWM. It is noteworthy that in the human system the sensitivity of 
the assay is not enhanced by hapten conjugation of the SRBC to the great extent 
that is seen in the mouse system (3, 19). The reason for this is unclear at present, 
but  it  may  merely  represent  fundamental  species differences in  the  hapten 
specificities of the  B-cell repertoire.  Nonetheless,  the magnitude  and  consist- 
ency of the PWM-induced PFC  response  against  even unconjugated  SRBC is 
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define more precisely the specific requirements for B-cell activation.  It is clear, 
for example, that the PFC response of B cells to PWM stimulation in this system 
is T-cell  dependent  since  removal  of T  cells  from  the  suspensions  results  in 
abolishment  of the  PFC  response. 2 This  is  consistent  with  the  findings  of 
Janossy and Greaves (20) in human tonsil and Keightley et al.  (21) in human 
peripheral  blood using the presence  of intracytoplasmic  Ig in plasma  cells as 
their assay. In addition, the response to SRBC stimulation is enhanced by an in 
vitro  allogeneic effect (Fig.  3) similar  to that  described in mice  (22),  further 
supporting  the  parallelism  between  the  present  model  and  numerous  well- 
defined mouse studies. 
The finding of polyclonal activation of B lymphocytes by substances such as 
LPS, PPD, and KLH is of particular interest. Such substances are known B-cell 
activators in mouse cultures (3), but they have not been shown to be mitogenic 
for human lymphocytes as measured by blast transformation. In particular, LPS 
has been shown to be ineffective in stimulating lymphocytes from human tonsil 
(23) or blood (24) to blast transformation. In the present study, blast transforma- 
tion was either totally or almost totally absent after stimulation with LPS, yet 
substantial PFC responses were detected. Stimulation with DxSO4 on the other 
hand resulted in neither a  proliferative nor an antibody response. These find- 
ings are quite consistent with the theories that B lymphocytes are made up of 
distinct subpopulations at various stages of differentiation,  which can respond 
in  a  variety  of ways  (proliferation,  antibody  secretion,  neither,  or  both)  to 
activation with different B-cell activators (3, 20,  25). 
Endotoxin contamination of these B-cell activators could not entirely explain 
the responses seen in these studies since, when present, endotoxin was found in 
nanogram quantities while true endotoxin stimulation with LPS required con- 
centrations of 50/~g/ml or greater for detectable PFC responses. In addition, SIII 
contained  endotoxin  and  did  not give significant  PFC  responses while  KLH 
contained no detectable endotoxin, yet resulted in substantial PFC responses in 
some individuals.  Finally,  substances such as PPD almost always exhibited a 
dose-response phenomenon with suppression of PFC at supraoptimal concentra- 
tions.  If endotoxin was responsible for all the PFC responses seen, one would 
expect a linear increase in PFC response with increasing concentrations,  given 
the  extremely  small  amount  of endotoxin  present  in  the  contaminated  sub- 
stances. 
Thus,  these studies provide a  simple,  sensitive,  and reproducible system of 
induction and assay of antibody production by human  lymphocytes after anti- 
genic stimulation,  as well as polyclonal activation of B cells. This model can be 
readily employed to explore the complex factors, cell requirements, and interac- 
tions involved in the activation of human B lymphocytes. 
Summary 
A model for the detection of single cell antibody production by human tonsil- 
lar lymphocytes aider stimulation  with either sheep red blood cells (SRBC) or 
polyclonal B-cell activators has been described. The culture system is a modified 
Mishell-Dutton technique with certain critical factors identified. The assay is a 
2 Fauci, A. S.,  and K. R. Pratt.  Manuscript in preparation. ANTHONY  S.  FAUCI  AND  KAREN  R.  PRATT  683 
sensitive  and  reproducible  hemolysis-in-gel system employing an  ultra-thin 
layer gel technique measuring plaque-forming cells  (PFC) against SRBC tar- 
gets.  Several  factors essential  for optimal  responses  are  described,  but  the 
critical feature of the culture system is the use of selected lots of human AB 
serum supplements which are extensively absorbed with SRBC. This removes a 
blocking factor  present  in  most  human  serum  which  suppresses  the  B-cell 
response to SRBC targets afLer stimulation with either SRBC or several poly- 
clonal B-cell activators. In addition, absorption of serum with SRBC eliminates 
the presence of artifactual plaques.  Background PFC  are extremely low and 
stimulated cultures show significant and reproducible responses. These studies 
provide a  simple,  sensitive, and reproducible model for probing the complex 
events associated with activation of human B lymphocytes. 
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Department of Otolaryngology of the National Naval Medical Center, Bethesda, Md. for supplying 
the tonsils. 
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